已上市降糖药物对非酒精性脂肪性肝病的治疗前景

高鑫

doi:10.3969/j.issn.1001-5256.2021.06.005

已上市降糖药物对非酒精性脂肪性肝病的治疗前景

DOI: 10.3969/j.issn.1001-5256.2021.06.005

高鑫^,

复旦大学附属中山医院内分泌科，复旦大学代谢性疾病研究所，上海 200032

利益冲突声明：所有作者均声明不存在利益冲突。

详细信息

作者简介:
高鑫(1955—)，女，教授，博士生导师，主要从事肥胖、糖尿病、胰岛素抵抗与脂肪肝的临床与基础研究

通信作者:
高鑫，gao.xin@zs-hospitail.sh.cn

中图分类号: R575.5
计量
- 文章访问数: 592
- HTML全文浏览量: 149
- PDF下载量: 83
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-04
- 录用日期: 2021-05-04
- 出版日期: 2021-06-20

Prospects of marketed hypoglycemic drugs in treatment of nonalcoholic fatty liver disease

Xin GAO^,

Department of Endocrinology and Metabolism, Fudan Institute for Metabolic Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)是代谢综合征在肝脏的表现，与糖脂代谢紊乱密切关联且互为因果，胰岛素抵抗是共同的发病机制。约3/4的肥胖和2型糖尿病患者患有NAFLD，目前指南建议将减少代谢危险因素和治疗代谢综合征作为NAFLD患者的主要治疗目标。虽然目前尚无针对非酒精性脂肪性肝炎的治疗药物，但是已经上市的降糖药物在降低血糖的同时可使NAFLD不同程度的获益。评述了已上市降糖药(噻唑烷二酮类、肠促胰素受体激动剂、钠-葡萄糖共转运体-2抑制剂)对NAFLD的治疗前景。
- 非酒精性脂肪性肝病 /
- 胰高血糖素样肽-1受体 /
- 过氧化物酶体增殖物激活受体 /
- 钠-葡萄糖转运体2
Abstract: Nonalcoholic fatty liver disease (NAFLD) is the manifestation of metabolic syndrome in the liver and is closely associated with glucose and lipid metabolism disorders, and they interact as both cause and effect of each other, with insulin resistance as the common pathogenesis. About three quarters of patients with obesity and type 2 diabetes mellitus have NAFLD, and current guidelines recommend reducing metabolic risk factors and treating metabolic syndrome as the primary treatment goals for patients with NAFLD. Although there are no approved drugs for the treatment of NASH at present, the hypoglycemic drugs on the market can bring varying degrees of benefits to NAFLD patients while lowering blood glucose. This article reviews the prospects of three types of hypoglycemic drugs on the market (thiazolidinediones, GLP-1 receptor agonists, and SGLT-2 inhibitors) in the treatment of NAFLD.
- Non-alcoholic Fatty Liver Disease /
- Glucagon-Like Peptide-1 Receptor /
- Peroxisome Proliferator-Activated Receptors /
- Sodium-Glucose Transporter 2

HTML全文

参考文献(12)

[1]	STEFAN N, HäRING HU, CUSI K. Non-alcoholic fatty liver disease: Causes, diagnosis, cardiometabolic consequences, and treatment strategies[J]. Lancet Diabetes Endocrinol, 2019, 7(4): 313-324. DOI: 10.1016/S2213-8587(18)30154-2.
[2]	NEUSCHWANDER-TETRI BA. Therapeutic Landscape for NAFLD in 2020[J]. Gastroenterology. 2020;158(7): 1984-1998. e3. DOI: 10.1053/j.gastro. 2020.01.051.
[3]	ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multi-centre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet. 2016, 387(10019): 679-690. DOI: 10.1016/S0140-6736(15)00803-X.
[4]	LV X, DONG Y, HU L, et al. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review[J]. Endocrinol Diabetes Metab, 2020, 3(3): e00163. DOI: 10.1002/edm2.163.
[5]	NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124. DOI: 10.1056/NEJMoa2028395.
[6]	KHAN RS, BRIL F, CUSI K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease[J]. Hepatology, 2019, 70(2): 711-724. DOI: 10.1002/hep.30429.
[7]	GASTALDELLI A, CUSI K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options[J]. JHEP Rep, 2019, 1(4): 312-328. DOI: 10.1016/j.jhepr.2019.07.002.
[8]	SUMIDA Y, YONEDA M, TOKUSHIGE K, et al. Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis[J]. Int J Mol Sci, 2020, 21(6): 1907. DOI: 10.3390/ijms21061907.
[9]	FRANCQUE S, SZABO G, ABDELMALEK MF, et al. Nonalcoholic steatohepatitis: The role of peroxisome proliferator-activated receptors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 24-39. DOI: 10.1038/s41575-020-00366-5.
[10]	CUSI K, ORSAK B, BRIL F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial[J]. Ann Intern Med, 2016, 165(5): 305-315. DOI: 10.7326/M15-1774.
[11]	SANYAL A, CHALASANI N, KOWDLEY K et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362(12): 1675-1685. DOI: 10.1056/NEJMc1006581.
[12]	GHARAIBEH NE, RAHHAL MN, RAHIMI L, et al. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: Pathophysiology, clinical outcomes, and future directions[J]. Diabetes Metab Syndr Obes, 2019, 12: 1001-1012. DOI: 10.2147/DMSO.S212715.